Chronic hepatitis C and chronic kidney disease: Advances, limitations and unchartered territories

DSpace/Manakin Repository

Chronic hepatitis C and chronic kidney disease: Advances, limitations and unchartered territories

Show simple item record

dc.contributor.author Mendizabal, Manuel.
dc.contributor.author Reddy, K.R.
dc.date.accessioned 2019-11-21T21:44:34Z
dc.date.available 2019-11-21T21:44:34Z
dc.date.issued 2017-01-20
dc.identifier.citation J Viral Hepat. 2017 Jun;24(6):442-453 en_US
dc.identifier.issn 1352-0504
dc.identifier.uri https://riu.austral.edu.ar/handle/123456789/785
dc.description.abstract Over the past few years, treatment options for chronic hepatitis C virus (HCV) infection have evolved dramatically. The current approved interferon-free direct-acting antiviral (DAA) regimens have been shown to be safe and effective with sustained virologic response (SVR) rates of >90% in most patients. Unique issues yet remain such as the challenges in patients with impaired renal function or decompensated cirrhosis. Patients with stages 4-5 chronic kidney disease (CKD) have a higher prevalence of HCV infection compared with the general population. Chronic HCV in those on dialysis and in kidney transplant recipients is associated with higher morbidity and mortality than uninfected patients. The HCV-infected population is also at risk of developing extrahepatic manifestations associated with altered immune system function and chronic inflammation with cryoglobulinaemic vasculitis being the most common of these manifestations. Therefore, patients with CKD stages 4-5 have to be considered priority patients for HCV therapy. New antiviral therapies have the potential to improve outcomes in this vulnerable patient population, including those on haemodialysis. Recently published studies conducted in kidney transplant recipients have demonstrated successful outcomes. It is thus essential that we carefully select the most appropriate DAA regimen and the best time for treatment in the context of kidney transplantation or cryoglobulinaemic vasculitis. While sofosbuvir, the only approved nucleotide NS5B inhibitor, has been the backbone of most pangenotypic therapeutic regimens, it has a limitation in those with advanced kidney disease. The currently approved regimens for those with stage 4/5 CKD, while effective, have challenges in that they apply to genotype 1/4 and may require RBV for genotype 1a. Globally, genotype 3 is a common infection, and thus, this group with CKD presents a huge unmet need for effective therapies. As therapy of HCV in renal transplant recipients has been highly successful, it provides an opportunity to expand the use of HCV-infected organs in solid organ transplantation. en_US
dc.language.iso en en_US
dc.publisher Wiley en_US
dc.subject Direct antiviral agents en_US
dc.subject End-stage renal disease en_US
dc.subject Hepatitis C en_US
dc.subject Kidney transplantation en_US
dc.title Chronic hepatitis C and chronic kidney disease: Advances, limitations and unchartered territories en_US
dc.type Article en_US


Files in this item

Files Size Format View Description
J Viral Hepat. 2017 Jun;24(6);442-453.pdf 118.0Kb PDF View/Open IA - Mendizabal

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account